Kyrgyzstan Medical Device Labeling, IFU and Packaging: Requirements and Best Practices

1. Key takeaways

In Kyrgyzstan, device labeling and instructions for use are provided in Russian and/or Kyrgyz, and their content must state the place of manufacture and the authorized representative information, the registration number, and storage and conditions of use, among other elements. The technical requirements are found in Decision No. 27: paragraph 2 of Article 2 of Cabinet of Ministers Resolution No. 513 references that decision, whose very title covers the requirements for marking and operational documentation. Label finalization should be moved forward into the technical documentation phase, because changing a label after certification triggers the amendment procedure. Planning label content, language and format while the dossier is still being drafted is the cheapest way to avoid a formal amendment cycle after approval.

2. Legal basis

1. Resolution No. 513 of the Cabinet of Ministers, dated August 27, 2024: the title of the resolution includes requirements for the marking and packaging of medical devices; paragraph 2 of Article 2 references Decision No. 27, whose full title covers the General Requirements for the Safety and Effectiveness of Medical Devices and the Requirements for Their Marking and Operational Documentation (with item 63 excluded).
2. Decision No. 27 of the Council of the Eurasian Economic Commission, dated February 12, 2016: the requirements for marking and operational documentation.
3. Law No. 216, Article 14: registration requires a positive expert assessment; Article 15: providing false information constitutes a ground for revocation of the registration certificate.
4. Law No. 216, Article 31: import is prohibited for devices with less than one third of their total shelf life remaining (excluding devices without a shelf life).
5. Website of the competent authority: forms and guidance are published bilingually in Kyrgyz and Russian.

Note on sources: the language requirement for labeling and instructions for use is described across sources as Russian and/or Kyrgyz; verbatim official implementing details were not obtained for this edition, and the statements below reflect the requirements as currently in force.

3. Expert insights

Insight 1: The title of Resolution No. 513 itself places marking and packaging within its scope.

The full title of the resolution addresses, among other things, the registration of medical devices, monitoring of safety, quality and effectiveness, and the requirements for marking and packaging. This means labeling is not merely one component of the technical file; it is a matter regulated directly by a Cabinet resolution. Companies have no first-to-market, fix-labels-later latitude: a label change is an amendment to the registration dossier and requires review approval (see article 35 of this series). Treating label design as a registration-stage deliverable rather than a marketing-stage afterthought is the correct reading of the legal architecture.

Insight 2: The title of Decision No. 27 includes marking and operational documentation, making it a dual-content document.

This structure means the technical basis for label requirements sits inside Decision No. 27 itself, with no need to hunt through other instruments. We recommend extracting, during label design, the items of Decision No. 27 concerning marking and operational documentation into a standalone labeling checklist. This is more reliable than following EU practice or company habit, because the checklist inherits the binding numbering that the reviewer will apply during assessment and during distribution-stage inspections alike.

Insight 3: The label is the first thing inspectors look at during circulation-stage checks.

Article 16 of this series explains that inspections can be launched independently at the distribution stage under Cabinet Resolution No. 450. The most visible item, and the one where inconsistencies are easiest to spot, is the label. Mismatches between the label and the registration dossier record (an outdated authorized representative, an incomplete model list, a missing registration number) are high-frequency nonconformities in circulation inspections. A quarterly reconciliation between labels in print and the dossier on file catches most of these before an inspector does.

Insight 4: Bilingual labeling is not one translation but two layers of requirements.

Kyrgyz is the state language and Russian is an official language. In practice, regulatory communication and document submission proceed mainly in Russian, while labels and instructions for use aimed at end users may need to be in Kyrgyz. We recommend confirming the requirement separately for each product category and sales channel, and finalizing the label only after receiving a written reply from the authorized representative, rather than making the choice unilaterally between the two languages.

Insight 5: Shelf-life labeling interacts directly with the prohibited import situations.

Article 31 of Law No. 216 prohibits importing devices with less than one third of their total shelf life remaining. This means the way the manufacturing date and expiry date are printed on the label directly affects whether goods clear customs. We recommend a labeling format that makes the remaining shelf life easy to calculate, showing both the manufacturing date and the expiry date, and avoiding formats that state only a shelf-life duration and invite calculation disputes at the border.

4. Practical recommendations

First, finalize the label during the technical documentation phase. Complete label design early in dossier preparation so that it matches the dossier record exactly. Any change to the label after certification is an amendment subject to review approval.

Second, build a labeling checklist mapped to Decision No. 27. At minimum it should cover: product name and model; manufacturer name and address; production sites; authorized representative name and contact details; registration number; batch or serial number; country of origin; storage and conditions of use; sterilization method and shelf life; and warnings and precautions.

Third, confirm the language requirement in writing before finalizing. Have the authorized representative obtain written confirmation from the competent authority on the language requirement, archive the reply, and use it as the documented basis for the label language decision.

Fourth, adopt a labeling format that makes remaining shelf life easy to calculate. Show both the manufacturing date and the expiry date, avoiding disputes at customs clearance caused by different calculation conventions.

Fifth, bring label changes into the change management procedure. Provide that any modification to the label, including wording, symbols and layout, is assessed for its impact on the registration dossier and processed through the amendment procedure.

5. Verification checklist

• □ Marking and operational documentation items extracted from Decision No. 27 into a labeling checklist;
• □ Label content covers: product name and model; manufacturer name and address; production sites; authorized representative name and contact details; registration number; batch or serial number; country of origin; storage and conditions of use; sterilization method and shelf life; warnings and precautions;
• □ Language requirement confirmed in writing by the authorized representative, with the reply archived before finalization;
• □ Label format shows both the manufacturing date and the expiry date;
• □ Label finalized during the technical documentation phase, matching the registration dossier record exactly;
• □ Label modifications are covered by the change management procedure, with every modification assessed for dossier impact.

Regulatory information verified as of October 29, 2026.

Our services cover: pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance support, post-market surveillance and device vigilance system setup, import and distribution compliance, and fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registration. We maintain a stable local cooperation network in Bishkek, Almaty, Tashkent and Moscow, work in Chinese, Russian and English, and provide executable solutions for foreign manufacturers on the issues most commonly encountered in CIS markets: authorized representative arrangements, notarization and legalization chains for powers of attorney, technical documentation localization, and inspection readiness. GRZAN supports manufacturers, importers and authorized representatives throughout the Kyrgyzstan registration lifecycle.

We adhere to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Any figure or timeframe that cannot be verified is labeled as a practical estimate and is never presented as a legal requirement.

For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services